This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

Efficacy and SafetyClinical Efficacy RAORAL StrategyReal-World EvidenceORAL Surveillance and Integrated Safety SummaryClinical Efficacy PsAOPAL Clinical ProgrammeClinical Efficacy UCOCTAVE Study DesignOCTAVE Clinical ProgrammeSub GroupsPost-hoc AnalysesSafety and TolerabilitySafety Profile SummarySpecial Warnings & Precautions for UseAboutXELJANZ Mechanism of ActionDosing and AdministrationDosing in RA & PsADosingDosing in UCDosingSupport & ResourcesSupport & ResourcesMaterials
Post-hoc Analyses UC Patients can benefit from a rapid and significant reduction in symptoms with XELJANZ, seen as early as 3 days1

For patients with moderately to severely active ulcerative colitis, onset of action is an important consideration when choosing appropriate therapy to provide timely symptomatic relief1

Based on post-hoc analyses of daily patient diary data from the OCTAVE induction studies:

  • Significant reductions in rectal bleeding vs placebo were seen as early as 3 days:
    mean change from baseline rectal bleeding subscore of -0.30 vs -0.14; p<0.01
  • Significant reductions in stool frequency vs placebo were seen as early as 3 days:
    mean change from baseline stool frequency subscore of -0.27 vs -0.11; p<0.01
Relates to results from a post hoc analysis, consideration should be made for multiple testing and inclusion of unadjusted p-values when interpreting data.Post-hoc analysis of pooled data from Induction 1 and 2 trials. Daily Mayo stool frequency and rectal bleeding subscores were calculated using patient diary data collected daily during the first 15 days of induction therapy. Partial Mayo Score subscore data were first collected at Day 15.With XELJANZ, rapid reductions in symptoms, seen within 3 days, are irrespective of prior tumour necrosis factor inhibitor (TNFi) therapy failure status, baseline steroid use, or baseline
C-reactive protein level1Percentage of patients with reduction from baseline Mayo rectal bleeding subscore ≥ 1 excludes patients with baseline Mayo rectal bleeding subscore = 0Percentage of patients with reduction from baseline Mayo stool frequency subscore of ≥ 1 excludes patients with baseline Mayo stool frequency subscore = 0Explore more We have resources available for you and your patients See Resources Loading

Please refer to the XELJANZ Summary of Product Characteristics for full prescribing information

References:Hanauer S et al. Clin Gastroenterol Hepatol 2019;17:139-47.Hanauer S et al Clin Gastroenterol Hepatol 2019;17(Suppl):139-47.XELJANZ Summary of Product Characteristics.
Clinical Efficacy in UC
SAFETY

Learn more about the XELJANZ safety profile

 See safety profile summary
DOSING

Learn about dosing in UC

 See recommended dosing
MECHANISM OF ACTION

Find out more about how XELJANZ works

 See how XELJANZ works

Legal Category: S1A
Further information is available upon request

PP-XEL-IRL-0782 January 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No